Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline

H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in
clinical development by initiating phase I clinical studies with Lu
02-750 in order to investigate safety, tolerability and the
pharmacokinetic profile of the drug in humans. The placebo-controlled
study is expected to enrol around 100 healthy individuals.

Lu 02-750 is a dopaminergic agent acting on brain areas affected in
Parkinson's disease. In animal models, the compound has demonstrated
very convincing effects as compared to conventional treatments.
Expectations are that the compound can offer Parkinson's patients a
new and higher level of disease control.

"Focus at Lundbeck Research is to discover new innovative treatments
that address unmet needs and offer clear benefits to the patients and
we believe that Lu 02-750 has the potential to improve the treatment
and life quality of patients suffering from Parkinson's disease",
says Executive Vice President Peter Høngaard Andersen, Head of
Research at Lundbeck and continues: "Lundbeck is actively pursuing
external technologies and collaborations and Lu 02-750 has been
discovered in close collaboration with Professor Håkan Wikström,
Groningen University and Axon Biochemicals B.V."

About Parkinson's disease
Parkinson's disease is an age-related degenerative disorder of the
brain. Symptoms can include tremor, stiffness, slowness of movement
and impaired balance. An estimated four million people worldwide
suffer from the disease, which usually affects people over the age of
60.
Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79              +45 36 43 28 51

Palle Holm Olesen            Kasper Riis
Head of Investor Relations   Media Relations
+45 36 43 24 26              +45 36 43 28 33

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.